Effects of in vivo administration of epidermal growth factor (EGF) on uterine contractility, prostaglandin production and timing of parturition in rats.
Prostaglandins synthesized by cyclooxygenases elicit uterine contractions during labour. Nitric oxide synthases (NOS) produce nitric oxide (NO), which maintains uterine quiescence during pregnancy. Epidermal growth factor (EGF) interacts with prostaglandins and NO in many biological systems. The aim of this work was to study the effect of the in vivo administration of EGF on uterine contractility, prostaglandin production and timing of parturition in rats. EGF was injected into the uterine lumen of pregnant rats on day 20, 21 or 22 of gestation. Intra-uterine administration of 500 ng EGF on day 21 of gestation delayed parturition for 18 h compared with control rats. Administration of EGF was able to: (i) reduce cyclooxygenase expression in the uterus (determined by western blot analysis) and production of prostaglandins by the uterus (evaluated by conversion of [(14)C]arachidonate to labelled prostaglandins); (ii) decrease prostaglandin concentrations in amniotic fluid (radioimmunoassay); (iii) increase NO production (evaluated by conversion of [(14)C]arginine into [(14)C]citrulline); (iv) increase serum progesterone concentrations to more than control concentrations (P<0.05; radioimmunoassay); and (v) reduce the amplitude of the uterine contractions. The overall effect was a delay in the onset of delivery. This in vivo effect raises the question of whether exogenous EGF plays a role in the initiation of parturition.
Ribeiro
M L
ML
Laboratorio de Fisio-patología de la Preñez y el Parto, Centro de Estudios Farmacológicos y Botánicos (CEFYBO, CONICET), Serrano 669, 3rd Floor, C1414DEM, Bs. As. Argentina. marialribeiro@yahoo.com.ar
Farina
M
M
Aisemberg
J
J
Franchi
A
A
D000653:Amniotic Fluid / Q000378:metabolism; D000818:Animals; D003864:Depression, Chemical; D015237:Dinoprost / Q000096:biosynthesis; D004815:Epidermal Growth Factor / Q000494:pharmacology*; D005260:Female; D007743:Labor, Obstetric / Q000187:drug effects*; D009569:Nitric Oxide / Q000378:metabolism; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D011453:Prostaglandins / Q000096:biosynthesis*; D011458:Prostaglandins E / Q000096:biosynthesis; D051381:Rats; D017208:Rats, Wistar; D014590:Uterine Contraction / Q000187:drug effects*; D014599:Uterus / Q000187:drug effects / Q000378:metabolism*
D011453:Prostaglandins; D011458:Prostaglandins E; D009569:Nitric Oxide; D011374:Progesterone; D004815:Epidermal Growth Factor; D015237:Dinoprost; D011451:Prostaglandin-Endoperoxide Synthases